4.7 Article

The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease

Related references

Note: Only part of the references are listed.
Article Neurosciences

Presynaptic Alpha-Synuclein Aggregation in a Mouse Model of Parkinson's Disease

Kateri J. Spinelli et al.

JOURNAL OF NEUROSCIENCE (2014)

Review Biochemical Research Methods

Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies

Adrien W. Schmid et al.

MOLECULAR & CELLULAR PROTEOMICS (2013)

Review Clinical Neurology

Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder?

C. Warren Olanow et al.

MOVEMENT DISORDERS (2013)

Review Neurosciences

The many faces of alpha-synuclein: from structure and toxicity to therapeutic target

Hilal A. Lashuel et al.

NATURE REVIEWS NEUROSCIENCE (2013)

Review Clinical Neurology

A Progressive Mouse Model of Parkinson's Disease: The Thy1-aSyn (Line 61) Mice

Marie-Francoise Chesselet et al.

NEUROTHERAPEUTICS (2012)

Review Biochemistry & Molecular Biology

Missing pieces in the Parkinson's disease puzzle

Jose A. Obeso et al.

NATURE MEDICINE (2010)

Article Clinical Neurology

The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia

JJ Zarranz et al.

ANNALS OF NEUROLOGY (2004)

Article Multidisciplinary Sciences

α-synuclein locus triplication causes Parkinson's disease

AB Singleton et al.

SCIENCE (2003)

Review Neurosciences

Alpha-synuclein and neurodegenerative diseases

M Goedert

NATURE REVIEWS NEUROSCIENCE (2001)